Nkarta, Inc. · NASDAQ:NKTX
Nkarta — Corporate Update (April 2022)
26 slides from Nkarta's corporate update, Apr 25, 2022
Slide 1: Clinical Program Update
Exhibit 99.2 Clinical Program Update 25 April 2022 Clinical Data as of 21 April 2022 1
Slide 2: Forward looking statements
Forward looking statements This presentation contains forward-looking statements, within the meaning of the Private Securities This presentation has been prepared by the company based on information it has obtained from Litigation Reform Act of 1995, regarding future events and the future results of
Slide 3: Best-in-class platform driving off-the-shelf CAR NK cell therapies
Best-in-class platform driving off-the-shelf CAR NK cell therapies Co-lead programs in hematologic malignancies NKX101 NKX019 OX40 costimulatory Targeting Targeting NKG2D ligands Targeting CD19 domain receptor CD3ζ signaling moiety • Phase 1 in r/r AML and • Phase 1 in r/r B cell higher-risk MDS mal
Slide 4: NKX101 and NKX019: Well tolerated and highly active in r/r AML and r/r NHL
NKX101 and NKX019: Well tolerated and highly active in heavily pre-treated r/r AML and r/r NHL patients, respectively • NKX101 - No DLTs or cases of CRS, GvHD or neurotoxicity - 3 of 5 patients achieved CR (60%) in r/r AML at highest two dose levels in 3 dose regimen - 2 out of 3 CRs were MRD negati
Slide 5: NKX101 for the Treatment of Relapsed/Refractory AML and Higher-Risk MDS
NKX101 for the Treatment of Relapsed/Refractory AML and Higher-Risk MDS 5
Slide 6: AML is a rapidly progressing leukemia with a poor prognosis
AML is a rapidly progressing leukemia with a poor prognosis Cancer of immature blood cells or “blasts” in the bone marrow • Treatment requires multiple rounds of intensive chemotherapy • Most patients will ultimately relapse, even after prior CR • Patients unfit for intensive chemotherapy may achiev
Slide 7: NKX101 Phase 1 Trial Design
NKX101 Phase 1 Trial Design • High-risk pre-treated Lymphodepletion NKX101 multi-dosing cycle Efficacy assessment patient population • Cyclophosphamide • Two dosing regimens: Either 2 or • Based on ELN criteria for - r/r AML or higher risk • Fludarabine 3 doses of CAR-NK per cycle AML, Cheson for MD
Slide 8: NKX101 patients were heavily pre-treated and multiply-relapsed with poor prognosis
NKX101 NKX101 patients were heavily pre-treated and multiply- relapsed with poor prognosis Total Characteristics (N=21) Age, median (range) 60 (22 - 76) 3 Median lines of prior therapy Diagnosis, AML/MDS, n 17/4 Baseline ECOG 1, n 12 Months since diagnosis, median (range) 13 (2 – 54) 100% 17 of 17 p
Slide 9: NKX101 was well-tolerated across all regimens and dose levels
NKX101 NKX101 was well-tolerated across all regimens and dose levels ≥ G3 AEs in > 1 subject Total (N=21) • No dose-limiting toxicities Hematologic Events - Currently enrolling cohort at 1.5 billion cells× 3 doses Thrombocytopenia 10 (48%) • Myelosuppression and infection consistent Febrile neutrope
Slide 10: Favorable dose response to increased cells per dose and doses per cycle in AML
NKX101 Favorable dose response to both increased number of cells / dose and number of doses / cycle in AML AML: ORR (CR, CRi, MLFS, PR) AML: CR MDS: ORR (CR, marrow CR, PR) NKX101 – 3 doses / cycle (Day 0, 7, 14) 1B / 1.5B x 3 3/5 (60%) 3/5 (60%) 2/3 MRD- 0/2 (0%) 4/6 (67%) 0/6 (0%) No patients trea
Slide 11: NKX101 drives AML blast reduction at all dose levels in 3 dose regimen
NKX101 NKX101 drives AML blast reduction at all dose levels in 3 dose regimen with some patients achieving MRD- Dose Baseline Best post-NK # Level marrow blasts response 1.5B × 3 13% PD 3/5 CR 8% CR (MRD-) at highest CR (MRD+) doses in 16% MLFS end of Cycle 1, 1B × 3 go-forward CR end of Cycle 2 3-d
Slide 12: NKX101 demonstrated clinical activity across dose levels in AML
NK NKX1 X10 01 1 NKX101 demonstrated clinical activity across dose levels in AML Dose Best Patient Cells Regimen Response Months on Study 1 1B CR (MRD-) 3 of 5 patients * 2 1B CR achieved CR at 3 1B PD highest doses in 4 1B CR (MRD-) go-forward 3-dose regimen 5 1.5B PD 6 100M MLFS 7 150M CRi 8 100M
Slide 13: Case Study: Molecular remission following NKX101
NKX101 Case Study: Molecular remission following NKX101 NKX101 detected after every dose Efficacy 3 doses of 1 billion CAR NK cells per dose Expected NK-like PK and clearance Day 20 Post- Cycle 1 assessment • CR, MRD- via FISH Patient Profile • Normocellular marrow • 68-year-old male Safety • AML wi
Slide 14: Summary: NKX101 was well-tolerated and highly active in heavily pre-treated AML patients
NKX101 Summary: NKX101 was well-tolerated and highly active in heavily pre-treated AML patients • No DLTs or cases of CRS, GvHD or neurotoxicity • 3 of 5 patients achieved CR (60%) in r/r AML at highest two dose levels in 3-dose regimen - 2 out of 3 CRs were MRD negative • Responses and blast reduct
Slide 15: NKX019 for the Treatment of Relapsed/Refractory B-Cell Malignancies
NKX019 for the Treatment of Relapsed/Refractory B-Cell Malignancies 15
Slide 16: Non-Hodgkin lymphomas are cancers derived from B cells
Non-Hodgkin lymphomas are cancers derived from B cells and include aggressive and indolent forms Subtypes of NHL • All forms express B-cell antigens, such as CD19 DLBCL (33%) • DLBCL has a poor prognosis and r/r disease is especially challenging Follicular lymphoma (22%) - 32-54% CR rate in r/r LBCL
Slide 17: NKX019 Phase 1 Trial Design
NKX019 Phase 1 Trial Design • High-risk, high-need patient population Lymphodepletion NKX019 multi-dosing cycle Efficacy assessment • Cyclophosphamide • 3 doses of CAR-NK per cycle • Based on Lugano criteria - r/r NHL, CLL and B-ALL • Fludarabine for NHL, NCCN for B-ALL - ≥2 prior therapies • Up to
Slide 18: NKX019 patients were heavily pre-treated, with a poor prognosis
NK NKX0 X01 19 9 Mirroring real-world CAR T, NKX109 patients were heavily pre-treated, with a poor prognosis Characteristic Total (N=13) Age, median (range) 54 (21-82) Baseline ECOG 1 7 Australia/US 10/3 50% 5 of 10 NHL patients with aggressive LBCL Diagnosis # Large B cell lymphoma 5 Follicular lym
Slide 19: NKX019 was well-tolerated across all dose levels
NKX019 NKX019 was well-tolerated across all dose levels • No dose-limiting toxicities up to 1 billion ≥ G3 AEs in > 1 subject Total (N=13) cells x 3 dose level Hematologic Events - Currently enrolling cohort at 1.5 billion cells× 3 Neutropenia 9 (69%) doses Thrombocytopenia 5 (38%) • Myelosuppressio
Slide 20: Favorable dose response in aggressive NHL with increased dose of NKX019
NKX019 Favorable dose response in aggressive NHL with increased dose of NKX019 NKX019 300M cells x 3 doses NKX019 1B cells x 3 doses ORR (CR, PR) CR ORR (CR, PR) CR All NHL 2/4 (50%) 1/4 (25%) 5/6 (83%) 3/6 (50%) # LBCL 1/3 (33%) 0/3 (0%) 1/2 (50%) 1/2 (50%) No patients treated No patients treated M
Slide 21: NKX019 drove responses in every NHL subtype treated
NKX019 NKX019 drove responses in every NHL subtype treated Dose Level Diagnosis Baseline Disease Best Response Nodal DLBCL CR Nodal, marrow MCL CR rd Nodal, liver, PR, now in 3 • Dose response observed FL Spleen cycle • Responses observed after single cycle 1B x 3 Nodal, extra-nodal MZL CR and acros
Slide 22: NKX019 provides rapid responses, including complete responses
NKX019 NKX019 provides rapid responses, including complete responses Best Patient Cells Diagnosis Response 1 1.0B x 3 DLBCL CR 3 CR and 2 PR 2 1.0B x 3 CR MZL among 6 PR, now in 3 1.0B x 3 FL rd patients with 3 cycle NHL treated 4 1.0B x 3 MCL CR with 3 doses of PR, now in 5 1.0B x 3 FL nd 2 cycle 1
Slide 23: Case studies: Single cycle, rapid complete responses with NKX019
NKX019 Case studies: Single cycle, rapid complete responses with NKX019 across doses in r/r NHL Patient Profile Patient Profile • 53-year-old male with • 73-year-old female with extensive DLBCL extensive high-risk FL • Relapsed after R- • Relapsed after R- EPOCH and R-ICE bendamustine, Efficacy refr
Slide 24: NKX019 shows preliminary activity and safety in NHL
NKX019 NKX019 shows compelling preliminary activity and safety in NHL with the potential to address multiple unmet needs • No DLTs or cases of CRS, GvHD or neurotoxicity • 5 of 6 patients responded (83% ORR) and 3 of 6 patients achieved complete response (50% CR) in NHL at 1B cells× 3 dose level - C
Slide 25: Potential upcoming milestones for clinical programs
Potential upcoming milestones for clinical programs 2022 2023 2024 H1 H2 H1 H2 H1 H2 Ph1 Dose Finding: 3 Dose Regimen Dose Expansion: Monotherapy Pivotal Trials: Monotherapy NKX101 AML Potential for fast track / RMAT / breakthrough Initial Data Dose Expansion: Combination therapy designation Release
Slide 26: Emerging clinical data from both NKX101 and NKX019 programs validate the Nkarta platform
ü Promising preliminary activity with favorable safety profiles Emerging clinical ü Allogeneic and off-the-shelf therapies data from both available on demand NKX101 and ü Potential to pursue accelerated regulatory NKX019 programs pathway options, earlier line combination validate the Nkarta regimens